• ADMA Biologics CEO Adam Grossman executed a pre-arranged sale of company shares.
• The transaction also involved the exercise of previously granted stock options.
• The activity represents insider trading carried out under an established trading plan.

For investors watching ADMA Biologics, ticker NasdaqGM:ADMA, this insider activity comes with the stock last closing at $15.95. The company’s long term track record includes very large returns over 3 and 5 years, while the 1 year return is close to flat at 1.4%. In the shorter term, the share price has seen a 7.9% decline over the past 30 days and a 10.8% decline year to date.

Insider transactions like this can be routine, especially when tied to option exercises and pre-set plans. However, they still draw attention because they offer a window into how executives manage their exposure to the stock. As you look at NasdaqGM:ADMA, this move may be one factor to weigh alongside the company’s recent share price performance and your own risk tolerance.

Stay updated on the most important news stories for ADMA Biologics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on ADMA Biologics.

Quick Assessment

• ✅ Price vs Analyst Target: At $15.95, ADMA Biologics trades about 38% below the analyst consensus target of $25.67.
• ✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading 66.3% below fair value, indicating a valuation discount.
• ❌ Recent Momentum: The stock has seen a 7.9% decline over the past 30 days.

There is only one way to know the right time to buy, sell or hold ADMA Biologics. Head to Simply Wall St's company report for the latest analysis of ADMA Biologics's Fair Value.

Key Considerations

• 📊 The pre arranged sale and option exercise by the CEO looks like planned portfolio management, so you may want to weigh it against the sizeable gap between price and analyst target.
• 📊 Watch how the P/E of 18.1 compares to the Biotechs industry average of 22.2, as well as any updates to analyst targets and insider trading disclosures.
• ⚠️ The key flagged risk is a high level of non cash earnings, so it is worth checking the quality and sustainability of profits when assessing this insider move.

Dig Deeper

For the full picture including more risks and rewards, check out the complete ADMA Biologics analysis. Alternatively, you can check out the community page for ADMA Biologics to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.